Table 1
Clinical characteristics at the time of initial NSCLC diagnosis
| Characteristic | N = 120 n (%) |
|---|---|
| Smoking history | |
| Current smoker | 7 (6) |
| Former smoker | 33 (28) |
| Never smoker | 76 (63) |
| Unknown | 4 (3) |
| ECOG performance status | |
| 0 | 28 (23) |
| 1 | 62 (52) |
| 2 | 22 (18) |
| 3 | 6 (5) |
| 4 | 1 (1) |
| Unknown | 1 (1) |
| Stage at initial diagnosis | |
| Early stage (I-II) | 13 (11) |
| Limited regional (IIIA) | 4 (3) |
| Locally advanced (IIIB) | 0 |
| Metastatic (IV) | 103 (86) |
| Site of distant metastases | |
| Adrenal | 12 (10) |
| Bone | 54 (45) |
| Brain | 33 (28) |
| Liver | 19 (16) |
| Lung | 60 (50) |
| Lymph nodes | 60 (50) |
| Peritoneal | 2 (2) |
| Pleura | 38 (32) |
| Skin/soft tissue | 3 (3) |
| Other* | 10 (8) |
Figure 1
(A) Kaplan-Meier curves for median real-world progression free survival on first-line (1L) epidermal growth factor (EGFR) tyrosine kinase inhibitors (TKIs) therapy. (B) Kaplan-Meier curves for median overall survival from start of 1L EGFR TKI therapy. Censored patients are indicated with a cross.
CI = confidence interval; OS = overall survival; rwPFS = real-world progression-free survival
Figure 2
Treatment patterns patients in with locally advanced or metastatic epidermal growth factor receptor mutated (EGFRm) non-small cell lung cancer (NSCLC) treated with first-line (1L) first-/second-generation (1G/2G) EGFR tyrosine kinase inhibitors (TKIs). Note that multiple treatments could have been administered at each line of treatment.
* Targeted therapy besides afatinib, erlotinib, gefitinib and osimertinib (1L: not specified; 3L: crizotinib); 2L = second-line; 3L =third-line; IO = immuno-oncology
Figure 3
Attrition rates at first-line (1L), second-line (2L) and third-line (3L) in patients with locally advanced or metastatic epidermal growth factor receptor mutated (EGFRm) non-small cell lung cancer (NSCLC).